Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck

Tinhofer, Ingeborg; Konschak, Robert; Stromberger, Carmen; Raguse, Jan Dirk; Dreyer, Johannes H.; Jöhrens, Korinna; Keilholz, Ulrich; Budach, Volker

doi:10.1093/annonc/mdu271

Cited by 75 publications

(60 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the routine use of CTC measurements for response evaluation is still not possible, due to the complexity of the method and missing standard protocols. Similar problems were previously encountered by other research groups [30,34,53,57,64] .…”

Section: Circulating Tumor Cellssupporting

confidence: 81%

See 1 more Smart Citation

Response Evaluation in Head and Neck Oncology: Definition and Prediction

Hoffmann¹,

Schuler²,

Laban³

et al. 2017

ORL

View full text Add to dashboard Cite

Curative treatment of head and neck squamous cell carcinoma includes surgery and/or (chemo)radiation, whereas in the palliative setting, chemotherapy and/or immunotherapy represent(s) the standard approach. With regard to quality control, methods for determining treatment response are sorely needed. For surgical therapy, histopathology is the standard quality control. Established criteria for high-risk patients include resection margins of the primary tumor and extracapsular extension of lymph node metastases. After definitive chemoradiation, treatment response is generally evaluated by tomographic imaging combined with endoscopy including re-biopsy of the tumor region. Single-cycle induction chemotherapy may be used to determine the radiosensitivity of tumors, helping to define surgical and nonsurgical treatment options. Innovative approaches with implications for prognosis include the analysis of immune infiltrates, liquid biopsy, molecular characterization (proteomics, genomics), molecular and functional imaging (PET-CT, PET-MRI), as well as advanced imaging data analysis (radio[geno]mics/texture analysis). Human papilloma virus, as a prognostically relevant parameter, is currently being investigated for de-escalation strategies. With regard to the extended personalization of oncologic therapy, markers predicting treatment response are desirable and seem to be important, also from a socioeconomic perspective.

show abstract

Section: Circulating Tumor Cellssupporting

confidence: 81%

“…However, validation in prospective cohorts is not yet available. So far, the prediction of therapy response by "liquid biopsy," analyzing CTC, tumor-derived circulating DNA, exosomes, or tumor-associated immune cells, could not be established in clinical routine [30,34,53,57,64] .…”

Section: Future Perspectivesmentioning

confidence: 99%

Response Evaluation in Head and Neck Oncology: Definition and Prediction

Hoffmann¹,

Schuler²,

Laban³

et al. 2017

ORL

View full text Add to dashboard Cite

show abstract

“…Interestingly, in the subset of OPCs within this dataset, CTCs were not predictive of disease free survival (DFS) or overall survival (OS). However, in non-OPCs, CTC were an independent prognostic marker of poorer DFS and OS [57]. Therefore, upon further validation, CTC quantification could prove to be a useful tool to identify patients who could benefit from treatment intensification.…”

Section: Determination Of Hpv Status and Hpv As A Biomarkermentioning

confidence: 99%

HPV Associated Head and Neck Cancer

Spence

Bruce

Yip

et al. 2016

Cancers

114

108

View full text Add to dashboard Cite

Head and neck cancers (HNCs) are a highly heterogeneous group of tumours that are associated with diverse clinical outcomes. Recent evidence has demonstrated that human papillomavirus (HPV) is involved in up to 25% of HNCs; particularly in the oropharyngeal carcinoma (OPC) subtype where it can account for up to 60% of such cases. HPVs are double-stranded DNA viruses that infect epithelial cells; numerous HPV subtypes, including 16, 18, 31, 33, and 35, drive epithelial cell transformation and tumourigenesis. HPV positive (HPV+) HNC represents a distinct molecular and clinical entity from HPV negative (HPV−) disease; the biological basis for which remains to be fully elucidated. HPV positivity is strongly correlated with a significantly superior outcome; indicating that such tumours should have a distinct management approach. This review focuses on the recent scientific and clinical investigation of HPV+ HNC. In particular, we discuss the importance of molecular and clinical evidence for defining the role of HPV in HNC, and the clinical impact of HPV status as a biomarker for HNC.

show abstract

“…However, in none of the three cases with persistent positive cytology was a visible tumor mass present. In patients with locally advanced squamous head and neck cancer, circulating tumor cells can be recovered from peripheral blood in which their number is related to stage of disease and may be associated with a worse prognosis following radical treatment . Although circulating tumor cells may serve as a marker for subsequent metastasis, their presence does not indicate that metastasis will definitely occur in those patients.…”

Section: Discussionmentioning

confidence: 99%

Tumor implantation following percutaneous endoscopic gastrostomy insertion for head and neck and oesophageal cancer: Review of the literature

Rowell

2019

Head & Neck

View full text Add to dashboard Cite

Background Because of publication bias, there is uncertainty about the true incidence of tumor seeding or implantation in patients with head and neck or oesophageal cancer undergoing percutaneous endoscopic gastrostomy (PEG) insertion. Methods In order to obtain a more reliable estimate of risk, a systematic review was undertaken. Randomized or non‐randomized studies and case reports were identified by electronic searching. A risk of bias assessment was carried out for each study. Results Ninety‐eight cases from 74 published case reports and 1 unpublished case were identified. Synchronous distant metastases were present in 37%. Analysis of case series (6192 patients) considered to carry a moderate risk of bias suggests an incidence of seeding after PEG insertion of 0.32%. Studies carrying a lower risk of bias indicate a risk of seeding closer to 1 in 2000. Conclusion The true risk of seeding after PEG insertion is probably less than 1 in 1000.

show abstract

Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck

Abstract: Assessment of CTC in non-OPC should prove useful for identification of patients who benefit from treatment intensification. The basis for the good prognostic value of CTC in OPC has to be elucidated in future studies.

Cited by 75 publications

References 19 publications

Response Evaluation in Head and Neck Oncology: Definition and Prediction

Response Evaluation in Head and Neck Oncology: Definition and Prediction

HPV Associated Head and Neck Cancer

Tumor implantation following percutaneous endoscopic gastrostomy insertion for head and neck and oesophageal cancer: Review of the literature

Contact Info

Product

Resources

About